Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

VICC toll-free number 1-877-936-8422

Gastrointestinal Cancers

The Gastrointestinal (GI) Oncology Program focuses on malignancies of the esophagus, stomach, small intestine, colon, rectum, anus, liver, gallbladder, pancreas and bile ducts.

Clinical Trials for Gastrointestinal Cancers

29 Open Trials

Trial Type Protocol No. &
Open Date
Summary

Basic Science

VICCGI0283

06/01/2002

Novel Gastrointestinal Cancer Markers in Tissue and Biofluids

Diagnostic

Liver

VICCGI14124

03/13/2015

PET Imaging of Hepatocellular Carcinoma with 18F-FSPG

Diagnostic

Liver

VICCGI1343

02/06/2014

Multi-Parametric 3 Tesla Magnetic Resonance Imaging (MRI) of Response to Transarterial Chemoembolization (TACE) in Patients with Hepatocellular Carcinoma (HCC)

Other

Liver

VICCGI1523

07/01/2015

Radiation-Emitting SIR-Spheres in Non-resectable (RESIN) Liver Tumor Patient Registry

Other

Colon
Rectum

VICCGI99003

08/01/2010

Personalized Prevention of Colorectal Cancer

Other

Colon
Rectal

VICCGI0721

01/09/2007

Vanderbilt Hereditary Colorectal Cancer Registry

Prevention

Colon

GIS0820-M

07/09/2013

A double blind placebo controlled trial of eflornithine and sulindac to prevent recurrence of high risk adenomas and second primary colon ca in patients with stage 0-III colon ca; phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac

Supportive Care

Colon
Rectal

VICCGI1549

08/04/2015

PROGRAMS TO SUPPORT YOU DURING CHEMOTHERAPY (PRO-YOU) A randomized controlled pilot study of yoga compared to an attention control in 60 patients receiving chemotherapy

Treatment

Liver

VICCGI1586

07/31/2015

A Humanitarian Device Exemption Treatment Protocol of TheraSphere? for Treatment of Primary Liver Cancer

Treatment

VICCGIP1520

07/21/2015

A Phase 1, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability, and Pharmacokinetic Study of TAS102 in Combination with CPT11 in Patients with Advanced Gastrointestinal Tumors

Treatment

Rectal

VICCGI1491

07/15/2015

A Double-Blind, Randomised, Placebo Controlled Phase III Study of Nintedanib plus Best Supportive Care (BSC) versus Placebo Plus BSC in Patients with Colorectal Cancer Refractory to Standard Therapies.

Treatment

Miscellaneous

VICCPHI14136

07/02/2015

An open-label, Phase I, dose-escalation trial to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti- FGFR2 antibody drug conjugate BAY 1187982 in subjects with advanced solid tumors known to express FGFR2

Treatment

Colon
Rectal

VICCGI14109

07/01/2015

An Open-Label Expanded Access Study of TAS-102 in Patients with Metastatic Colorectal Cancer Refractory to or Failing Standard Chemotherapy

Treatment

Pancreatic

VICCGI1506

06/29/2015

A Phase II, Single-arm, Open-label, Bayesian Adaptive Efficacy and Safety Study of PBI-05204 in Patients with Stage IV Metastatic Pancreatic Adenocarcinoma

Treatment

Pancreatic

VICCGI1507

06/16/2015

NAB-PACLITAXEL (ABRAXANE) plus Gemcitabine in Subjects with Locally Advanced Pancreatic Cancer (LAPC): An International, Open-Label, Multi-Center, Phase 2 Study (LAPACT)

Treatment

Colon
Rectal

VICCGI14104

06/08/2015

Randomized, Blinded, Multicenter, Phase 2 Study Comparing Veliparib Plus FOLFIRI ? Bevacizumab Versus Placebo Plus FOLFIRI ? Bevacizumab in Previously Untreated Metastatic Colorectal Cancer

Treatment

Neuroendocrine
Pancreatic

ECOGGIE2211

03/04/2015

A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients with Advanced Pancreatic Neuroendocrine Tumors

Treatment

VICCGI1497

01/27/2015

A Multi-Institutional, Single-Arm, Two-Stage Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients with Advanced or Metastatic Cholangiocarcinoma

Treatment

Pancreatic

VICCGI1417

12/17/2014

A Phase 1b Dose Escalation Study of OMP-54F28 in Combination with Nab-Paclitaxel and Gemcitabine in Patients with Previously Untreated Stage IV Pancreatic Cancer

Treatment

Pancreatic

VICCGI1405

08/07/2014

A Phase 3, Multicenter, Open-Label, Randomized Study of nab?-Paclitaxel Plus Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy in Subjects with Surgically Resected Pancreatic Adenocarcinoma

Treatment

Esophageal
Gastric/Gastroesophageal

VICCGI13114

08/04/2014

A Two Part, Phase 1, Multi-center, Open-label Study of DKN-01 in Combination with Weekly Paclitaxel; Arm A: A Dose-Escalation Study in Patients with Relapsed or Refractory Esophageal Cancer or Gastro-esophageal Junction Tumors; Arm B: An Expansion Cohort in Patients with Relapsed or Refractory Esophageal Cancer or Gastro-esophageal Junction Tumors

Treatment

Colon
Rectal

VICCGI13101

06/24/2014

Randomized, Double-Blind, Phase II Trial of Vitamin D Supplementation in Participants with Previously Untreated Metastatic Colorectal Cancer

Treatment

Bladder
Colon
Esophageal
Gastric/Gastroesophageal
Neuro-Oncology
Ovarian
Urologic
Uterine

VICCMD1403

06/02/2014

An Open Label, Phase II Study of Neratinib in Patients with Solid Tumors with Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification

Treatment

Esophageal
Gastric/Gastroesophageal
Lung
Non Small Cell
Pancreatic

VICCPHI1360

04/22/2014

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination with Chemotherapy in Subjects with Advanced Solid Tumors

Treatment

Pancreatic

VICCGI1370

12/30/2013

A Phase 1b Dose Escalation Study of Vantictumab (OMP-18R5) in Combination with Nab-Paclitaxel and Gemcitabine in Patients with Previously Untreated Stage IV Pancreatic Cancer

Treatment

Neuroendocrine
Pancreatic

VICCGI1250

04/09/2013

A Phase I/II Study of the Combination of Temozolomide and Pazopanib in Advanced Pancreatic Neuroendocrine Tumors (PNET)

Treatment

Adrenocortical
Bladder
Breast
Cervical
Colon
Dermatologic
Esophageal
GIST
Gastric/Gastroesophageal
Gynecologic
Head/Neck
Kidney (Renal Cell)
Liver
Lung
Multiple Myeloma
Neuroendocrine
Non Small Cell
Ovarian
Pancreatic
Prostate
Rectal
Sarcoma
Uterine

VICCMD1188

06/08/2012

An Open-Label, Phase II Study of Vemurafenib in Patients with BRAF V600 Mutation-Positive Cancers

Treatment

Liver

CTSUGI80702-M

05/05/2011

A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX plus Celecoxib or placebo for patients with Resected Stage III Colon Cancer

Treatment

Liver

CTSUGIC80802-M

12/07/2010

Phase III randomized study of sorafenib (IND 69896, NSC 724772) plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC)